THERAPY DOSSIER · th-be59cdb57494

Hyperforin (active constituent of Hypericum perforatum)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT07397325 ↗PHASE1/PHASE2not yet recruiting

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

Chemotherapy Induced Alopecia · Chemotherapy Side Effects

Enrolment: 60 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28870826 ↗2017Reported benefit

Hyperforin protects against acute cerebral ischemic injury through inhibition of interleukin-17A-mediated microglial activation.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57BL/6 wild-type and interleukin-17A knock-outMaleIntracerebroventricular injection into the right ventricle0.5 microgram per injectionFirst dose 1 h after onset of middle cerebral artery occlusion

Model: Middle cerebral artery occlusion for 60 min followed by 72 h reperfusion

Hyperforin reduced infarct volume and improved neurologic scores at 72 h, decreased interleukin-17A expression and microglial activation and promoted M2 polarisation; recombinant interleukin-17A abolished these protective effects.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.

Loading the evidence…